The Obesity ETF SLIM
33.25 USD 0.00 (+0.00%)
Mar 12, 2020, 3:59 PM EDT
33.00 Day range 36.62
33.00 52-week range 43.40
News
zacks.com 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
globenewswire.com Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects Strong NPM-139 safety and tolerability profile: -0 of 10 NPM-139 subjects experienced adverse events reported as treatment related -5 of 10 Wegovy subjects (control group) experienced adverse events…
marketbeat.com iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline iBio NASDAQ: IBIO expects to report initial data from its clinical-stage myostatin program in the first quarter of the next calendar year and begin dosing patients in a separate Activin E study…
fool.com Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company,…
marketbeat.com Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data Corbus Pharmaceuticals NASDAQ: CRBP has started a Phase 3 study of its cancer drug CRB-701 and expects an exploratory readout from a separate frontline combination study in the first quarter of next…